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annuluswasmeasured as 25mmindiameter and aortoventricular anat-
omywithin horizontal lying (Fig. 1A, B). In cardiac catheterization espe-
cially left anterior oblique 10° cranial, serial aortic root injections also
revealed the aortoventricular angle. Transfemoral route didn't ﬁt for
purpose because of large degree of aortic root angulation. Because of
speciﬁc anatomic consideration, transfemoral TAVI performed as off-Introduction
TAVI has been becoming a mainstay of treatment of severe aortic
stenosis in patients who have a high estimated risk of surgical valve
replacement.1,2 Unfavorable anatomical structures can induce technical
difﬁculties like high or low valve deployment which can also occur
following implantation appear to be more common with the CV.
The low or high positioning may be associated with paraprosthetic re-
gurgitation, device embolization and impact atrioventricular node,
resulting hemodynamic instability.3 Herein, we aimed to delineate
pre-procedural root angulation prediction and performing maneuvers
for optimal device deployment and abstain from complications.Case report 1
An 80 year old man admitted with increasing dyspnea (New York
Heart Association functional Class-III) and palpitation for last 1 month.
On physical examination, the patient had signs of pulmonary conges-
tion and cardiovascular auscultation revealed aortic stenosis murmur.
Baseline transthoracic echocardiography revealed a calciﬁed aortic
valve, mean velocity of 3.9 m/sn, mean transvalvular gradient of
42mmHg. Left ventricular ejection fractionwas 40%. His coronary angi-
ography revealed calciﬁed plaque in the epicardial coronary arteries. His
calculated Logistic Euro Score was 14.2% and Society of Thoracic
Surgeons (STS) score was 5%. Due to the patient had low risk, the
heart team decided to perform surgical aortic valve replacement
(SAVR) but the patient refused SAVR and decided to proceed with
TAVI. So, the heart team approached for off-label TAVI. Multidetector
computed tomography (MDCT) documented bilateral ilio-femoralaculty of Medicine, Dokuz Eylül




my. Production and hosting by Elsearteries which had minimum diameter of 10.1 mm in right side, aortic
label indication. TAVI was performed under local anesthesia the patient
evaluated one month later. A Novaﬂex+ (Edwards Lifesciences, Inc.)
deployment catheter was inserted through the right common femoral
artery. Pre-implantation balloon valvuloplasty was done with a
25 ∗ 40 mm balloon with good expansion. The 29 mm ESV alignment
and deployment was done under ﬂuoroscopic guidance with “two
step deployment technique” including pull back Amplatz Extra-Stiff J-
tip guidewire (COOK, Bjaeverskov, Denmark) by about a centimeter
and then, ﬂoppy tipped guidewire was rotated clockwise providing co-
axial alignment. After the deployment, ﬂuoroscopic control showed
normal bioprosthetic valve function and there is no leakage (Fig. 2).Case report 2
A 71 year old woman admitted to arising from gradual onset of ex-
ertional dyspnea for last 1 year. The patient had a past medical history
of coronary artery bypass graft. On cardiovascular auscultation, there
was a grade 3/6 systolic murmur in aortic focus. Baseline transthoracic
echocardiography revealed several calciﬁed changes of aortic valve
with mean transvalvular gradient of 38 mm Hg and mean velocity of
4.1m/sn. Left ventricular ejection fractionwas 60%. Cardiac catheteriza-
tion revealed severe coronary artery disease with 70% narrowed diffuse
lesion of left anterior descending artery and with 100% occluded left in-
ternalmammary artery. The Logistic Euro Score and STSwere calculated
to be 32% and 9%. Because of high surgical risk, the heart team
approached for TAVI. MDCT evaluation prior to TAVI revealed minimal
bilateral ilio-femoral luminal diameter of 8.2 mm, aortic annulus was
measured as 26 mm and changes in anatomical structures of aortic
rootwhichhad broad aortoventricular angle (Fig. 3A, B). In cardiac cath-
eterization, left anterior oblique 10° cranial position revealed large de-
gree of aortic root. Transfemoral TAVI was performed under general
anesthesia as off-label indication due to very calciﬁed bilateral subclavi-
an arteries. A right femoral cutdownwas performed and then, the 18 Fr
CV delivery catheter was indwelled into the right common femoral
artery. Balloon aortic valvuloplasty was performed under rapidvier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. A. The maximum and minimum aortic annulus diameter and annulus area. B.
Calciﬁed aortic valve and aortoventricular angle was measured as 73.28° in coronal
plane of multidetector computed tomography.
Fig. 3. A. The maximum and minimum aortic annulus diameter and annulus area. B.
Calciﬁed aortic valve and aortoventricular angle was measured as 75° in coronal plane of
multidetector computed tomography.
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positioning was based on ﬂuoroscopy guidance with “two step de-
ployment technique” including pull back Amplatz Super-Stiff J-tip
guidewire by about a centimeter and then, ﬂoppy tipped guidewire
was rotated clockwise providing coaxial alignment. Then, CV wasFig. 2. Left anterior oblique image of the Edwards Sapien Valve had normal function.deployed under supra-annular aortography during right ventricular
pacing. Post-procedural aortography showed suitable position of
the CV with no valvular and paravalvular leakage (Fig. 4).
Discussion
Horizontal aortic root with a vertical annulus is ascribed technical
challenge in TAVI. Preprocedural MDCT offers detailed aortic root
anatomy. Understanding of root anatomy plays key role for certain
alignment and accurate positioning of the bioprosthesis valve.4 Cor-
onal oblique projection in the MDCT provides aortoventricular angu-
lation deﬁned as the angle between left ventricle and ascending
aorta 40 mm above the aortic annulus.5 If angulation is N70°,
transfemoral and left subclavian approaches are contraindicated. Es-
pecially transfemoral approach within excessive angulation limits
the capability to control the tension on delivery catheter during de-
vice release may lead to implant failure. Alternative routes such as
transaortic, transaxillar accesses are utilized to ensure more effort-
less device manipulation in these cases.3,4 Edwards NovaFlex's steer-
able catheters can facilitate controlled position and following route
in challenging anatomies including horizontal aorta.6 Furthermore,
U.S. Food and Drug Administration approves for the CV Evolut R
transcatheter valve and the EnveoR delivery system in June 2015.
EnveoR's capsule ﬂare and ﬂexible catheter offer navigation of unfa-
vorable anatomical structures. This catheter provides the option of
repositionability.7 Finally, Chan et al. performed several different
maneuvers in a patient with horizontal aorta implanted CV
Fig. 4. Left anterior oblique image of the Core Valve had normal function.
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introducing of back-end of the guidewire, retracting the delivery sys-
tem without guidewire and the last maneuver is re-introducing soft
tip of the guidewire and pushing the delivery system towards the
ventricular side gradually.4In conclusion, preprocedural imaging techniques especially MDCT
plays as a central role in a planning prior to procedural approaching
and deciding to apply suitable technical management. In this man-
ner, the number of the patients with horizontal aorta implanted
bioprosthesis valve may be increased, transfemoral TAVI may apply
in this condition more commonly.Conﬂict of interest
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